Press Releases

Date	Title
December 8, 2022	Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
December 8, 2022	Corcept Therapeutics Provides Miricorilant Clinical Development Update
November 3, 2022	Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
October 27, 2022	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 11, 2022	Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
August 3, 2022	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 27, 2022	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
June 29, 2022	Corcept Therapeutics Initiates ROSELLA – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
June 6, 2022	Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
May 5, 2022	Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update